Novo Nordisk A/S v. Ikon Health LLC

District Court, E.D. Washington·Decided June 30, 2025·No. 4:24-cv-05093·Unknown

Opinion

1 EASTERN DISTRICT OF WASHINGTON Jun 30, 2025 2 SEAN F. MCAVOY, CLERK 3 4 5 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF WASHINGTON 6 NOVO NORDISK A/S and NOVO 7 NORDISK INC., CASE NO: 4:24-CV-05093-RLP 8 Plaintiffs, ORDER GRANTING IN PART JOINT 9 v. MOTION FOR REVISED STIPULATED PROTECTIVE ORDER 10 IKON HEALTH LLC d/b/a/ INVIGOR 11 MEDICAL, LLC, 12 Defendants. 13 Before the Court is the parties’ Joint Motion for Entry of Revised Stipulated 14 Protective Order, ECF No. 35. The parties seek a protective order to protect 15 confidential material including: (1) trade secrets or other competitively sensitive, 16 non-public, technical, research, development, marketing, financial, accounting, 17 employment, commercial, or other confidential business information; (2) private or 18 confidential personal information or personal health information; and (3) 19 information over which the designating party is obligated to maintain 20 confidentiality by law or contract. ECF No. 35-1. 1 The parties ask the Court to sign a Protective Order that was drafted and 2 agreed to by the parties. It is this Court’s preference to not enter general Protective 3 Orders that simply set forth the parties’ agreement for handling “confidential” 4 materials. As noted below, the Court finds the first and second categories of

5 “confidential material” as defined by the parties to be vague and overbroad, and 6 declines to issue a protective order with regards to these categories. 7 However, the Court finds good cause under Fed. R. Civ. P. 26(c) to issue an

8 order to protect the some of categories of information identified by the parties in 9 this case. If the parties have other, specifically identified materials they believe to 10 be the proper subjects of a protective order, they may bring another motion or 11 stipulated order before the Court for its consideration.

12 ACCORDINGLY, IT IS ORDERED that the parties’ Joint Motion for 13 Entry of Revised Stipulated Protective Order, ECF No. 35, is GRANTED in part 14 and DENIED in part.

15 STIPULATED PROTECTIVE ORDER 16 1. Purpose 17 Disclosure and discovery activity in this action are likely to involve 18 production of confidential, proprietary, or private information for which special

19 protection from public disclosure and from use for any purpose other than for the 20 purpose of prosecuting this litigation may be warranted. Accordingly, Plaintiffs Novo Nordisk A/S and Novo Nordisk Inc. and Defendant Ikon Health LLC 1 (collectively, the “Parties”) petition this Court to enter the following Stipulated 2 Protective Order (“Protective Order”). This Protective Order governs documents, 3 the information contained therein, and other information produced or disclosed 4 during this litigation.

5 2. Definitions 6 “Designating Party” means a Party or Non-Party that designates 7 a. something it has produced in this proceeding as “Confidential” or

8 “Attorney’s Eyes Only.” 9 “In-House Counsel” means attorneys who are employees of a party to 10 b. this action. In-House Counsel does not include Outside Counsel of 11 Record or any other outside counsel.

12 “Non-Party” means a person or entity not named as a party in this action 13 c. that has occasion to produce Disclosures, e.g., in response to a subpoena. 14 “Outside Counsel of Record” means attorneys who represent parties in

15 d. this litigation for purposes of this litigation. 16 “Party” means any party to this litigation, including all of its officers, 17 e. directors, employees, consultants, retained experts, In-House Counsel, 18 and Outside Counsel of Record.

19 “Protected Health Information” (“PHI”) has the same scope and 20 f. definition as set forth in the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended by the Health 1 Information Technology for Economic and Clinical Health Act 2 (“HITECH Act”), including all applicable regulations and guidance 3 issued by the Secretary of the United States Department of Health and 4 Human Services (collectively “HIPAA Rules”), including specifically 42

5 C.F.R. Part 2, and 45 C.F.R. §§ 164.506(c)(3), 164.512(e)(1)(ii)(B), 6 164.512(e)(1)(v), as well as all state laws and regulations regarding the 7 privacy and security of personal information (collectively with the

8 HIPAA Rules, “Privacy and Security Rules”) as well as the definitions 9 and guidance set forth in 45 C.F.R. § 160.103 and § 164.501. Without 10 limiting the generality of the foregoing, PHI includes, but is not limited 11 to, health information, including demographic information, relating to:

12 the past, present, or future physical or mental health or condition of an 13 individual; and the provision of health care to an individual, which 14 identifies or reasonably could be expected to identify the individual. It

15 also includes all notes, summaries, compilations, extracts, abstracts, or 16 oral communications that are based on or derived from PHI including 17 payment for care provided to an individual, regardless of form or format. 18 PHI also includes information that contains the following identifiers of a

19 patient: 20 i. names; 1 ii. all geographic subdivisions smaller than a State, including 2 street address, city, county, precinct, and zip code; 3 iii. all elements of dates (except year) directly related to an 4 individual, including birth date and age;

5 iv. telephone numbers; 6 v. fax numbers; 7 vi. electronic mail addresses;

8 vii. social security numbers; 9 viii. medical record numbers; 10 ix. health plan beneficiary numbers; 11 x. account numbers;

12 xi. certificate/license numbers; 13 xii. vehicle identifiers and serial numbers, including license plate 14 numbers;

15 xiii. device identifiers and serial numbers; 16 xiv. web universal resource locaters (“URLs”); 17 xv. internet protocol (“IP”) address numbers; 18 xvi. biometric identifiers, including finger and voice prints;

19 xvii. full face photographic images and any compatible images; 20 xviii. any other unique identifying number; characteristic, or code; and 1 xix. any other information that the Producing Party knows could be 2 used alone or in combination with other information to identify 3 an individual who is subject of the information. 4 “Protected Material” means any information, document or thing or

5 g. portion of any document or thing:1 (1) that contains PHI; or (2) 6 information over which the designating party is obligated to maintain 7 confidentiality by law, contract, or otherwise, all of which the

1 The Court finds the parties’ stipulation that “any document or thing that 9 contains trade secrets, or other competitively sensitive, non-public, technical, research, development, marketing, financial, accounting, employment, commercial 10 or other such confidential business information” constitutes “protected material” is vague and overbroad. 11 “Generally, the public can gain access to litigation documents and 12 information produced during discovery unless the party opposing disclosure shows 13 ‘good cause’ why a protective order is necessary.” Phillips ex rel. Ests. of Byrd v. Gen. Motors Corp., 307 F.3d 1206, 1210 (9th Cir. 2002). “For good cause to exist, 14 the party seeking protection bears the burden of showing specific prejudice or harm will result if no protective order is granted.” Id. at 1210-11.

Free access — add to your briefcase to read the full text and ask questions with AI

Novo Nordisk A/S v. Ikon Health LLC, (E.D. Wash. 2025).

Novo Nordisk A/S v. Ikon Health LLC (Novo Nordisk A/S v. Ikon Health LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related